ORIGINAL RESEARCH article
Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1542792
Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China
Provisionally accepted
- 1Drug Safety and Policy Research Center, School of Pharmacy, Xi’an Jiaotong University, Xi'an, Shaanxi Province, China
- 2department of pharmacy administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, xi'an, China
- 3Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Health Science Centre, Peking University, Beijing, Beijing Municipality, China
- 4International Research Center for Medicinal Administration, Peking University, Beijing, Beijing Municipality, China
- 5Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical Universiy, Fujian Provincial Hospital, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
head and neck cancers (HNC) head and neck squamous cell carcinoma (HNSCC) Chinese Society of Clinical Oncology (CSCO) programmed cell death protein-1 (PD-1) Food and Drug Administration (FDA) adding low-dose nivolumab to triple metronomic chemotherapy (TMC-I) overall survival (OS) confidence interval (CI) triple metronomic chemotherapy (TMC) partitioned survival model (PSM) quality-adjusted life years (QALYs) progression-free survival (PFS) progressive disease (PD) incremental cost-effectiveness ratios (ICERs) willingness-to-pay (WTP) Chinese gross domestic product (GDP) eastern cooperative oncology group performance status (ECOG PS) best supportive care (BSC) Kaplan-Meier (KM) individual patient data (IPD) Akaike information criterion (AIC) Bayesian information criterion (BIC) adverse events (AEs) deterministic sensitivity analysis (DSA) probabilistic sensitivity analyses (PSA) cost-effectiveness acceptability curves (CEACs) progression-based (PB) time-to-death (TTD) previous treatment (Rx)
Keywords: Cost-Effectiveness, low-dose nivolumab, triple metronomic chemotherapy, Head and neck squamous cell carcinoma, partitioned survival model
Received: 05 Feb 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Cao, Shi, Li, Wei, Yi, Han and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yu Fang, department of pharmacy administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.